# A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis

> **NCT04175613** · PHASE3 · COMPLETED · sponsor: **Amgen** · enrollment: 160 (actual)

## Conditions studied

- Psoriasis

## Interventions

- **DRUG:** Apremilast

## Key facts

- **NCT ID:** NCT04175613
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-12-20
- **Primary completion:** 2025-10-30
- **Final completion:** 2025-12-12
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04175613

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04175613, "A Long-term Extension Study of Apremilast (CC-10004) in Pediatric Subjects From 6 Through 17 Years of Age With Moderate to Severe Plaque Psoriasis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT04175613. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*